Oncotarget: Tumor spheroid model in mesothelioma and lung cancers

Oncotarget published "Optimization of tumor spheroid model in mesothelioma and lung cancers and anti-cancer drug testing in H2052/484 spheroids" which reported that human mesothelioma and lung tumor spheroids were established from cell lines and primary cells derived from the patient.

The growth kinetics and cell viability of microtumors were assessed using spheroid size and intracellular ATP level.

These authors determined that studying the kinetics of the spheroid growth for 15 days after seeding 1000 cells/well in a 96-well plate was optimal.

Monitoring the growth kinetic and intracellular ATP of spheroids allowed the identification of early changes in spheroid viability.

Finally, they validated this model by measuring a dose-dependent reduction in the cell viability of mesothelioma H2052/484 spheroids treated with both first-line treatments, cisplatin and the cisplatin/pemetrexed combination.

Dr. Véronique Serre-Beinier from The University Hospitals and University of Geneva said, "Cancer is the second leading cause of death globally, accounting for an estimated 9.9 million deaths in 2020."

Cancer is the second leading cause of death globally, accounting for an estimated 9.9 million deaths in 2020

Lung cancers are classified into two main types:

1. Non-small-cell lung carcinoma, which accounts for 80–85 percent of all lung cancers, and

2. Small-cell lung carcinoma, which accounts for 10–15 percent.

In vitro three-dimensional tumour models, including patient-derived tumor organoid or spheroid models, have been developed successfully from different human cancers, including lung carcinoma.

The purpose of this study is to evaluate the reproducibility and accuracy of a multicellular tumor spheroid model of lung cancer and mesothelioma to predict the clinical efficacy of drugs.

Figure 6: Short-term effect of cisplatin or cisplatin/pemetrexed on viability of H2052/484 spheroids. H2052/484 spheroids (1,000 cells/spheroid) were untreated (control, black curve) or treated with compound for 3 hours at day 3 post-seeding. After washes, the spheroids were cultured for 24 hours and the ATPi levels were determined. Data are presented as the ratio of the ATPi levels of treated spheroid to control spheroid. The data represent the mean ± SD of 2 independent experiments.

In 2015, Weiswald LB et al., proposed a rational classification of the four most commonly used spherical cancer models: the multicellular tumor spheroid model; the tumorospheres; the tissue-derived tumor spheres and the organotypic multicellular spheroids.

Using commercially available cell lines and primary patient-derived cells, this research team created malignant pleural mesothelioma and lung tumor spheroids in vitro and validated these models to test the therapeutic efficiency of both first-line treatment.

The Serre-Beinier Research Team concluded in their Oncotarget Research Output, "we established a simple, reliable in vitro 3D tumor spheroid model that can be used to characterize the efficacy of anti-cancer drugs on primary cells derived from a patient diagnosed with mesothelioma or lung cancer."

Sign up for free Altmetric alerts about this article

DOI - https://doi.org/10.18632/oncotarget.28134

Correspondence to - Véronique Serre-Beinier - veronique.Serre-Beinier@hcuge.ch

Keywords - cancer patient, lung tumor, pleura mesothelioma, tumor spheroid, chemosensitivity

About Oncotarget

Oncotarget is a biweekly, peer-reviewed, open access biomedical journal covering research on all aspects of oncology.

To learn more about Oncotarget, please visit https://www.oncotarget.com or connect with:

SoundCloud - https://soundcloud.com/oncotarget
Facebook - https://www.facebook.com/Oncotarget/
Twitter - https://twitter.com/oncotarget
LinkedIn - https://www.linkedin.com/company/oncotarget
Pinterest - https://www.pinterest.com/oncotarget/
Reddit - https://www.reddit.com/user/Oncotarget/

Oncotarget is published by Impact Journals, LLC please visit https://www.ImpactJournals.com or connect with @ImpactJrnls

Media Contact
MEDIA@IMPACTJOURNALS.COM
18009220957x105